Irritable Bowel Syndrome

Primary Care - Clinics in Office Practice

Volumn 38, Issue 3, 2011, Pages 433-447

  Malone, Michael A ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Constipation; Diarrhea; Gastrointestinal disorder; Irritable bowel syndrome

Indexed keywords

ALOSETRON; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFLATULENCE AGENT; BENZODIAZEPINE DERIVATIVE; GABAPENTIN; GASTROINTESTINAL AGENT; LUBIPROSTONE; PEPPERMINT OIL; PLACEBO; PREGABALIN; PROBIOTIC AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ACUPUNCTURE; BLOATING; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL FEATURE; COGNITIVE THERAPY; CONSTIPATION; DEFECATION HABIT; DEFECATION URGENCY; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM INFLAMMATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; EPILEPSY; FECES MICROFLORA; FIBROMYALGIA; FLATULENCE; FOOD ALLERGY; GUT DIRECTED HYPNOTHERAPY; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC DISEASE; INFECTION COMPLICATION; IRRITABLE COLON; ISCHEMIC COLITIS; LOW DRUG DOSE; NEUROPATHIC PAIN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT REFERRAL; PHYSICAL EXAMINATION; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; STOMACH MOTILITY; STOMACH SECRETION; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PATIENT EDUCATION AS TOPIC; PHYSICAL EXAMINATION; PROBIOTICS;

EID: 80052346770     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.05.003     Document Type: Review

References (89)

1. Tillisch K., Labus J.S., Naliboff B.D., et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005, 100(4):896-904.
2. American Gastroenterological Association. Available at: Accessed July 1, 2010. http://www.gastro.org/patient-center/digestive-conditions/irritable-bowel-syndrome.
3. Park J.H., Byeon J.S., Shin W.G., et al. Korean J Gastroenterol 2010, 55(5):308-315. [in Korean].
4. Everhart J.E. Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991, 100(4):998-1005.
5. Schuster M.M. Diagnostic evaluation of the irritable bowel syndrome. Gastroenterol Clin North Am 1991, 20:269.
6. Sandler R.S., Everhart J.E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002, 122:1500.
7. Talley N.J., Zinsmeister A.R., Van Dyke C., et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991, 101:927.
8. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993, 38:1569.
9. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1. American College of Gastroenterology Task Force of Irritable Bowel Syndrome.
10. Hahn B.A., Saunders W.B., Maier W.C. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997, 42:2585.
11. Saito Y.A., Locke G.R., Talley N.J., et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000, 95:2816.
12. Thompson W.G., Irvine E.J., Pare P., et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002, 47:225.
13. Hungin A.P., Whorwell P.J., Tack J., et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003, 17:643.
14. Chial H., Camilleri M. Gender differences in irritable bowel syndrome. J Gender Specif Med 2002, 5:37-45.
15. Chang L., Heitkemper M. Gender differences in irritable bowel syndrome. Gastroenterology 2002, 123:1686-1701.
16. Locke G.R., Zinsmeister A.R., Talley N.J., et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000, 75:907-912.
17. Levy R.L., Jones K.R., Whitehead W.E., et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001, 121:799-804.
18. Morris-Yates A., Talley N.J., Boyce P.M., et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998, 93:1311-1317.
19. Delvaux M., Denis P., Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls: results of a multicentre inquiry: French Club of Digestive. Eur J Gastroenterol Hepatol 1997, 9:345-352.
20. Gwee K.A., Leong Y.L., Graham C., et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999, 44:400-406.
21. Mykletun A., Jacka F., Williams L., et al. Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome. An epidemiological population based study of women. BMC Gastroenterol 2010, 10:88.
22. American Gastroenterological Association. American Gastroenterological Association Medical position statement, irritable bowel syndrome. Available at: Accessed September 1, 2010. http://www.gastrojournal.org/article/S0016-5085(02)00480-8/fulltext%23section.
23. Kellow J.E., Phillips S.F. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987, 92:1885-1893.
24. Jepsen J.M., Skoubo-Kristensen E., Elsborg L. Rectosigmoid motility response to sham feeding in irritable bowel syndrome: evidence of a cephalic phase. Scand J Gastroenterol 1989, 24:53.
25. Agrawal A., Houghton L.A., Reilly B., et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009, 104:1998.
26. Lawal A., Kern M., Sidu H., et al. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006, 130(1):26-33.
27. Mayer E.A., Gebhart G.F. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994, 107:271-293.
28. Mertz H., Naliboff B., Munakata J. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109:40-52.
29. Dorn S.D., Palsson O.S., Thiwan S.I., et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007, 56:1202.
30. Lasser R.B., Bond J.H., Levitt M.D. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975, 293(11):524-526.
31. Zighelboim J., Talley N.J., Phillips S.F., et al. Visceral perception in irritable bowel syndrome: rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995, 40:819.
32. Silverman D.H., Munakata J., Ennes H., et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997, 112:64.
33. Mertz H., Morgan V., Tanner G., et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000, 118:842.
34. Bueno L., Fioramonti J., Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol 2000, 278:G670.
35. Willert R.P., Woolf C.J., Hobson A.R., et al. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 2004, 126:683.
36. Barbara G., DeGiorgio R., Cremon C., et al. A role for inflammation in irritable bowel syndrome?. Gut 2002, 51:41-44.
37. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002, 122:1778.
38. Liebregts T., Adam B., Bredack C., et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132:913.
39. Tornblom H., Lindberg G., Nyberg B., et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972.
40. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126:693.
41. Guilarte M., Santos J., de Torres I., et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56:203.
42. Kassinen A., Krogius-Kurikka L., Makivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007, 133:24.
43. Thabane M., Kottachchi D.T., Marshall J.K. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26:535-544.
44. Halvorson H.A., Schlett C.D., Riddle M.S. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006, 101:1894.
45. Everest P.H., Goossens H., Butzler J.P., et al. Differentiated Caco-2 cells as a model for enteric invasion by Campylobacter jejuni and E coli. J Med Microbiol 1992, 37:319.
46. Swain M.G., Blennerhassett P.A., Collins S.M. Impaired sympathetic nerve function in the inflamed rat intestine. Gastroenterology 1991, 100:675.
47. Niaz S.K., Sandrasegaran K., Renny F.H., et al. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 1997, 31:53.
48. Sinha L., Liston R., Testa H.J., et al. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 1998, 12:839.
49. Muldoon C., Maguire P., Gleeson F. Onset of sucrase-isomaltase deficiency in late adulthood. Am J Gastroenterol 1999, 94:2298.
50. Parry S.D., Stansfield R., Jelley D., et al. Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003, 98:327.
51. Ilnyckyj A., Balachandra B., Elliott L., et al. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003, 98:596.
52. Longstreth G.F., Thompson W.G., Chey W.D., et al. Functional bowel disorders. Gastroenterology 2006, 130:1480.
53. Swarbrick E.T., Bat L., Hegarty J.E., et al. Site of pain from the irritable bowel. Lancet 1980, 2:443.
54. Manning A.P., Thompson W.G., Heaton K.W., et al. Towards a positive diagnosis of the irritable bowel. Br Med J 1978, 2:653.
55. Whorwell P.J., McCallum M., Creed F.H., et al. Non-colonic features of irritable bowel syndrome. Gut 1986, 27:37.
56. Hershfield N.B. Nongastrointestinal symptoms of irritable bowel syndrome: an office-based clinical survey. Can J Gastroenterol 2005, 19:231.
57. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108.
58. Talley N.J., Phillips S.F., Melton L.J., et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990, 31:77.
59. Smith R.C., Greenbaum D.S., Vancouver J.B., et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991, 100:591.
60. Taub E., Cuevas J.L., Cook E.W., et al. Irritable bowel syndrome defined by factor analysis: gender and race comparisons. Dig Dis Sci 1995, 40:2647.
61. Tibble J.A., Sigthorsson G., Foster R., et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002, 123(2):450-460.
62. Camilleri M., Choi M.G., et al. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997, 11:3.
63. Kruis W., Thieme C., Weinzierl M., et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984, 87:1.
64. Frigerio G., Beretta A., Orsenigo G., et al. Irritable bowel syndrome: still far from a positive diagnosis. Dig Dis Sci 1992, 37:164.
65. Ford A.C., Chey W.D., Talley N.J., et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009, 169:651.
66. Cash B.D., Schoenfeld P., Chey W.D. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002, 97:2812.
67. Brandt L.J., Bjorkman D., Fennerty M.B., et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(11 Suppl):S7-S26.
68. Lynn R.B., Friedman L.S. Irritable bowel syndrome. N Engl J Med 1993, 329:1940.
69. Lackner J.M., Jaccard J., Krasner S.S., et al. How does cognitive behavior therapy for IBS work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007, 133(2):433-444.
70. Houghton L.A., Heyman D.J., Whorewell P.J. Symptomatology, quality of life and economic features of IBS: the effect of hypnotherapy. Aliment Pharmacol Ther 1996, 10(1):91-95.
71. Webb A.N., Kukuruzovic R.H., Catto-Smith A.G., et al. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2007, 4:CD005110.
72. Wald A., Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract 2008, 23:284.
73. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009, 58:367.
74. Talley N.J. Evaluation of drug treatment for irritable bowel syndrome. Br J Clin Pharmacol 2003, 56:362.
75. Harrison's principles of internal medicine 2008, McGraw-Hill publishing. 17th edition. A.S. Fauci, E. Braunwald, D.L. Kasper (Eds.).
76. Evans B.W., Clark W.K., Moore D.J., et al. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007, 4:CD003960.
77. Scott L.J., Perry C.M. Tegaserod. Drugs 1999, 58:491.
78. Gershon M.D. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003, 3(Suppl 2):S25.
79. Wiffen P., Collins S., McQuay H., et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2000, 2. CD001133.
80. Lee K.J., Kim J.H., Cho S.W. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22(10):981-988.
81. Houghton L.A., Fell C., Whorwell P.J., et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007, 56:1218-1225.
82. Drossman D.A., Chey W.D., Johanson J.F., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009, 29:329.
83. Macfarlane G.T., Cummings J.H. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health?. BMJ 1999, 318(7189):999-1003.
84. Yamazaki S., Kamimura H., Momose H., et al. Protective effect of bifidobacterium monoassociation against lethal activity of E coli. Bifidobacteria Microflora 1982, 1:55-60.
85. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Gastroenterology 2007, 132(2):813-816.
86. Guandalini S., Magazzù G., Chiaro A., et al. VSL#3 improves symptoms in children with IBS: a multicenter, randomized, placebo controlled, double blind, crossover study. J Pediatr Gastroenterol Nutr 2010, 51(1):24-30.
87. Grigoleit H.G., Grigoleit P. Peppermint oil in irritable bowel syndrome. Phytomedicine 2005, 12(8):601-608.
88. Ford A.C., Talley N.J., Spiegel B.M., et al. The effect of fiber, antispasmodics, and peppermint oil in IBS. Systematic review and meta-analysis. BMJ 2008, 337:1388-1392.
89. Lim B., Manheimer E., Lao L., et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006, 4:CD005111.